Compare AbCellera Biologics Inc (ABCL) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Manhattan Associates Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Manhattan Associates Inc trades at $153.94 (market cap $9.37B). The key difference: Manhattan Associates Inc is far larger — about 4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | MANH | |
|---|---|---|
Market Cap | $2.35B | $9.37B |
Sector | Health | Technology |
52-Week High | $8.12 | $227.94 |
52-Week Low | $2.78 | $120.88 |
Enterprise Value | $1.99B | $9.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MANH trades at $153.81, up 1.83% today, with a bullish technical outlook supported by moving averages and strong support at $150. The company demonstrates robust profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. However, valuation ratios appear elevated with a P/E of 43.1, while ongoing legal investigations pose sentiment risks.
The stock offers upside to the $192.80 consensus price target but faces headwinds from high valuation multiples and legal uncertainties. Earnings growth and cloud strategy execution remain key catalysts, though investors must weigh these against potential dilution from the fiduciary duty investigations highlighted repeatedly in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
